Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia

Neuroendocrinology Letters

Volumn 27, Issue 6, 2006, Pages 803-806

  Kopecek, Miloslav ^a   Bares, Martin ^a   Horacek, Jiri ^a   Mohr, Pavel ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

Anxiety; Depression; Endocrinology; Prolactinemia; Risperidone; Side effect

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DIBENZEPIN; ESCITALOPRAM; HYDROXYZINE; LAMOTRIGINE; MOOD STABILIZER; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTRALINE; VALPROIC ACID; VENLAFAXINE;

ADULT; AGE DISTRIBUTION; AGED; AMENORRHEA; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DOSE RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GALACTORRHEA; GENDER BIAS; HOSPITAL PATIENT; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; MALE; MENTAL PATIENT; MONOTHERAPY; MUSCLE RIGIDITY; PROLACTIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

EID: 33846444931     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Bartzokis G, Lu PH, Turner J, Mintz J, Saunders CS: Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry. 2005; 57:474-9.
2. Brawman-Mintzer O, Knapp RG, Nietert PJ: Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005; 66:1321-5.
3. Emiliano AB, Fudge JL. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology. 2004; 29(5):833-46.
4. Gagliano A, Germano E, Pustorino G, Impallomeni C, D'Arrigo C, Calamoneri F, Spina E: Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol. 2004; 14:39-47.
5. Haddad PM, Wieck A: Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004; 64:2291-314.
6. Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW: Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol. 2003; 18:1-8.
7. Kapur S, Langlois X, Vinken P, Megens AA, De CR, Andrews JS: The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther. 2002; 302:1129-34.
8. Kopecek M, Bares M, Svarc J, Dockery C, Horacek J: Hyperprolactinemia after low dose of amisulpride. Neuro Endocrinol Lett. 2004; 25:419-22.
9. Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR: Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry. 2005; 66:736-43.
10. Monnelly EP, Ciraulo DA, Knapp C, Keane T: Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol. 2003; 23:193-6.
11. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000; 57:794-801.
12. Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L: Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 1999; 156:869-875.
13. Ostroff RB, Nelson JC: Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999; 60:256-259.
14. Papakostas GI, Miller KK, Petersen T, Sklarsky KG, Hilliker SE, Klibanski A, Fava M. Serum Prolactin Levels Among Outpatients With Major Depressive Disorder During the Acute Phase of Treatment With Fluoxetine. J Clin Psychiatry. 2006; 67(6):952-7.
15. Sharpley AL, Bhagwagar Z, Hafizi S, Whale WR, Gijsman HJ, Cowen PJ: Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. J Clin Psychiatry. 2003; 64:192-6.
16. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002; 16:23-45.